株探米国株
英語
エドガーで原本を確認する
6-K 1 rdy0797_6k.htm FORM 6-K
 


SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

September, 2025

 

Commission File Number 1-15182

 

DR. REDDY’S LABORATORIES LIMITED

(Translation of registrant’s name into English)

 

8-2-337, Road No. 3, Banjara Hills

Hyderabad, Telangana 500 034, India

+91-40-49002900

 

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F  x                               Form 40-F   ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ______

 

Note:  Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ______

 

Note:  Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

 

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes  ¨                               No   x

 

If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.

 

 


 

EXHIBITS

 

Exhibit

Number

 

Description of Exhibits

 

 

 

99.1


Intimation dated September 1, 2025

 

2

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

DR. REDDY’S LABORATORIES LIMITED

(Registrant)

 

 

 

Date: September 1, 2025

By:

/s/ K Randhir Singh

 

 

Name: K Randhir Singh

 

 

Title:   Company Secretary

 

3
EX-99.1 2 rdy0797_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 


Dr. Reddy's Laboratories Ltd.

8-2-337, Road No. 3, Banjara Hills

Hyderabad – 500 034, Telangana, India

 

CIN: L85195TG1984PLC004507

 

Tel:       + 91 40 4900 2900

Fax:     + 91 40 4900 2999

Email: mail@drreddys.com

Web:   www.drreddys.com

 

September 1, 2025

 

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)

BSE Limited (Scrip Code: 500124)

New York Stock Exchange Inc. (Stock Code: RDY)

NSE IFSC Ltd. (Stock Code: DRREDDY)

 

Dear Sir/Madam,

 

Sub:

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Change in Senior Managerial Personnel

 

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we would like to inform that Ms. Archana Bhaskar has resigned from the position of Chief Human Resources Officer (CHRO) of the Company. She will cease to be CHRO and Senior Management Personnel of the Company, effective from the close of business hours on November 30, 2025. The resignation letter of Ms. Archana is annexed herewith.

 

The details required under Regulation 30 of the SEBI Listing Regulations, read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, is given in Annexure enclosed herewith.

 

This is for your information and records.

 

Thanking you,

 

Yours faithfully,

For Dr. Reddy’s Laboratories Limited


K Randhir Singh

Company Secretary, Compliance Officer and Head-CSR Details under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

 

Encl: as above

 

 


 

Annexure

 

 

Sl. No.

Particulars

Details

1

Reason for change viz. resignation,

Ms. Archana Bhaskar has resigned from the position of Chief Human Resources Officer (CHRO) of the Company to pursue other interests. She will cease to be CHRO and Senior Management Personnel of the Company, effective from the close of business hours on November 30, 2025

2

Date of cessation

November 30, 2025

3

Brief profile (in case of appointment)

Not applicable

 

4

Disclosure of relationships between directors (in case of appointment of a director)

Not applicable

 

 

September 1, 2025

 

To,

Erez Israeli

CEO

 

Dr. Reddy’s Laboratories Limited

 

Sub: My association with the company

 

Dear Erez,

 

Subsequent to our discussions, this note is to formalise my separation from the organisation to pursue other interests. I will be available to the Company till November 30, 2025.

 

I had a fulfilling 8+ years being part of this great organisation. Wishing the Company lots of success in the coming months and years.

 

Thank you and regards,


 

Archana Bhaskar

 

CHRO

   ​​​​​​​